Skip to content
Log in
Preprint

Accurate structural modeling of chemically diverse molecular interfaces with Vilya-2

Vilya Research Pascal Sturmfels Naozumi Hiranuma M. Salem Benjamin D. Sellers Stephen A. Rettie C. Felipe C. Wood Jeffrey K. Holden A. Moyer P. Salveson Ivan Anishchanka
Jul 2026 · 0 citations · 59 references
Computer Science

TL;DR

Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.

Abstract

Structure-prediction networks built on co-evolutionary statistics have transformed protein-based drug discovery, yet their accuracy does not extend to peptide therapeutics--an increasingly important modality defined by non-canonical residues, macrocyclization, and complex topologies. We introduce Vilya-2, a diffusion transformer that extends the all-atom representation of Vilya-1 from modeling individual molecules to modeling their interactions with protein targets. This all-atom representation enables transfer learning between different molecular types, and delivers highly accurate structural modeling of peptides across sizes, classes, and compositions bound to therapeutically relevant targets. By generating diverse structural ensembles and ranking them with calibrated confidence, Vilya-2 recovers 59.1% of peptide interfaces to sub-2 {\AA} backbone RMSD, far exceeding the performance of a representative co-folding model even when that model is given the bound receptor as a template. In addition, Vilya-2 is state-of-the-art at small-molecule docking, and generalizes to novel protein-small molecule complexes unlike those seen in training. It also generalizes to modeling molecular conformations of diverse macrocycles and disulfide-stapled miniproteins several-fold larger than any molecule seen in training. Finally, Vilya-2 can be used as a foundation model, and fine-tuned to enrich for active compounds in hit-to-lead campaigns. By unifying predictive accuracy with broad generalizability across chemical space, Vilya-2 is the structure-prediction oracle that de novo peptide design pipelines require--establishing the all-atom approach as a general foundation for the design and evaluation of de novo peptide therapeutics.

arXiv Semantic Scholar
View source

Similar papers

Preprint Jul 2026

Vilya-1: An all-atom foundation model for macrocycle structure prediction and design

Vilya-1 is introduced, a deep learning model that addresses two central challenges in macrocycle design: sampling biologically relevant conformations across arbitrary chemistries and predicting key developability properties such as membrane permeability.

Vilya Research Pascal Sturmfels, M. Salem, Naozumi Hiranuma et al. · 1 citation
Open access Aug 2026

Structure-free, site-resolved contrastive learning extends small-molecule discovery beyond the reach of structure-based modeling

Virtual screening asks which molecules, among an enormous space of drug-like chemistry, are worth synthesizing and testing against a protein target. Most modern methods answer this question by building and scoring an explicit three-dimensional pose through molecular docking, or the co-folding models that now approach experimental accuracy. Building these poses presumes a well-defined pocket. However, the non-orthosteric, cryptic, and intrinsically disordered sites where unexplored ligandability lies offer no such pocket to explore. Here we present Ptarmigan-1, a contrastive model that co-embeds the residues of a protein with candidate small molecules in a shared latent space, from sequence and two-dimensional chemistry alone, and without ever constructing a pose. Freed from the requirement for protein structures, Ptarmigan-1 trains directly on chemoproteomic and bioactivity data of mixed resolution, scores a compound in ten milliseconds rather than the tens of seconds a co-folding model demands, and resolves each prediction to the residues a compound engages. On well-folded, orthosteric targets it performs comparably to a collection of co-folding and docking models, and on covalent, cryptic, and disordered sites it matches or exceeds them. Ptarmigan-1 localizes reversible and covalent inhibitors to the pockets they engage, even for targets withheld from training, and screens the entire human proteome against a library of 3.4 billion compounds in under a day. By decoupling molecular recognition from structure, Ptarmigan-1 recasts virtual screening as a nearest-neighbor query in a rich latent space shared by protein residues and the compounds that bind them.

William E. Fondrie, Daniele Canzani, Lillian Tatka et al. · 1 citation
Open access Jul 2026

Mavchen-1: A Conformational Ensemble Platform for Protein–Ligand Pose Prediction That Substantially Outperforms Static Structure Prediction in a Category-Stratified Benchmark

A category-stratified, statistically powered benchmark comparing pose prediction from receptor conformational ensembles against AlphaFold2, used as a matched static-structure baseline, across 29 protein–ligand systems spanning cryptic-pocket, induced-fit, water-mediated, and autoimmune-indication target classes is presented.

Ryan Varghese, Pooja Tiwary, Krishil Oswal · 0 citations
Open access Aug 2026

On the generalization and usability of cofolding models for GPCR drug discovery

Boltz is benchmarked using a curated set of ligand-bound human G protein-coupled receptors from families unseen during training, showing that while Boltz generally predicts receptor backbones accurately, ligand poses can contain significant errors that lead to a limited ability to reproduce experimental affinity data when tested with FEP+.

Lichirui Zhang, R. Friesner, Edward B. Miller et al. · 0 citations